Indaptus Therapeutics, Inc.

INDP Nasdaq SEC CIK 1857044
Follow Indaptus Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$1M +64.7% vs same quarter last year
EPS, diluted −$0.01 +99.7% vs same quarter last year
Operating cash flow −$1.4M +44% vs same quarter last year
Operating income −$1.1M +57.1% vs same quarter last year
Net income by quarter
−$4.1M
−$4.5M
−$5.2M
−$3M
−$8.1M
−$2.5M
−$1.8M
−$1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$20.8M
FY24−$15M
FY23−$15.4M
FY22−$14.3M
FY21−$7.7M
FY20−$3.6M
FY19-